Unlike imatinib, nilotinib and other later-generationBCR-ABL inhibitors bind to p38α and inhibit the p38α-MK2/3signaling axis, which suppressed pro-inflammatory cytokine expression,cell adhesion, and innate immunity markers in activated monocytesderived from AML. This evidence concerns the gene ABL1 and acute myeloid leukemia.